Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy

McCaffrey, 1997, Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma, J Clin Oncol, 15, 1853, 10.1200/JCO.1997.15.5.1853 Roth, 1994, Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group, J Clin Oncol, 12, 2264, 10.1200/JCO.1994.12.11.2264 Bellmunt, 2009, Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract, J Clin Oncol, 27, 4454, 10.1200/JCO.2008.20.5534 Necchi, 2012, Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial, Lancet Oncol, 13, 810, 10.1016/S1470-2045(12)70294-2 Sweeney, 2006, Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium, J Clin Oncol, 24, 3451, 10.1200/JCO.2005.03.6699 Milowsky, 2013, Phase II study of everolimus in metastatic urothelial cancer, BJU Int, 112, 462, 10.1111/j.1464-410X.2012.11720.x Ko, 2013, Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study, Lancet Oncol, 14, 769, 10.1016/S1470-2045(13)70162-1 Powles, 2014, MPDL3280A (anti–PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904 Sharma, 2017, Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol, 10.1016/S1470-2045(17)30065-7 Massard, 2016, Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer, J Clin Oncol, 34, 3119, 10.1200/JCO.2016.67.9761 Bellmunt, 2017, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, 376, 1015, 10.1056/NEJMoa1613683 Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4 Sonpavde, 2016, Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma, J Urol, 195, 277 Bambury, 2015, The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience, Oncologist, 20, 508, 10.1634/theoncologist.2014-0354 Petrylak, 2018, Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: long-term outcomes from a phase 1 study, JAMA Oncol, 4, 537, 10.1001/jamaoncol.2017.5440 Choueiri, 2012, Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer, J Clin Oncol, 30, 507, 10.1200/JCO.2011.37.7002 Gallagher, 2010, Phase II study of sunitinib in patients with metastatic urothelial cancer, J Clin Oncol, 28, 1373, 10.1200/JCO.2009.25.3922 Lee, 2012, Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum, Invest New Drugs, 30, 1984, 10.1007/s10637-011-9757-7 Kim, 2016, A phase II study of weekly docetaxel as second-line chemotherapy in patients with metastatic urothelial carcinoma, Clin Genitourin Cancer, 14, 76, 10.1016/j.clgc.2015.09.008 Apolo, 2013, Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy, J Natl Cancer Inst, 105, 499, 10.1093/jnci/djt015 Necchi, 2017, Nomogram-based prediction of overall survival in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC), Eur Urol, 71, 281, 10.1016/j.eururo.2016.09.042 Powles, 2017, Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study, JAMA Oncol, e172411, 10.1001/jamaoncol.2017.2411 Patel, 2018, Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial, Lancet Oncol, 19, 51, 10.1016/S1470-2045(17)30900-2 Powles, 2018, Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 391, 748, 10.1016/S0140-6736(17)33297-X Bellmunt, 2010, Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens, J Clin Oncol, 28, 1850, 10.1200/JCO.2009.25.4599 Rimm, 2017, A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer, JAMA Oncol, 3, 1051, 10.1001/jamaoncol.2017.0013 Pond, 2015, Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design, Clin Genitourin Cancer, 13, 71, 10.1016/j.clgc.2014.06.004 Pond, 2014, A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma, BJU Int, 113, E137, 10.1111/bju.12564 Balar, 2017, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, Lancet, 389, 67, 10.1016/S0140-6736(16)32455-2 Balar, 2017, First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study, Lancet Oncol, 18, 1483, 10.1016/S1470-2045(17)30616-2